missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18000728

CXCR1/IL-8RA Antibody (MM0221-7D22), Allophycocyanin/Cy7, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-12237APCCY7

Product Code. 18000728

This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
 View alternative products »

This item is not returnable. View return policy

Description

Description

CXCR1/IL-8RA Monoclonal specifically detects CXCR1/IL-8RA in Human samples. It is validated for Flow Cytometry.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CXCR1/IL-8RA
Monoclonal
APC-Cyanine7
PBS with 0.05% Sodium Azide
CXCR1
Human recombinant CXCR1/IL-8RA
0.1 mL
Primary
Human
IgG2
Flow Cytometry
MM0221-7D22
Flow Cytometry
CD128, CD181, CD181 antigen, CDw128aC-C, chemokine (C-X-C motif) receptor 1, CKR-1, CMKAR1, C-X-C chemokine receptor type 1, CXC-R1, CXCR-1, High affinity interleukin-8 receptor A, IL-8 receptor type 1, IL-8R A, IL8R1, IL8RAC-C-CKR-1, IL8RBA, interleukin 8 receptor, alpha, interleukin-8 receptor type 1, interleukin-8 receptor type A
Mouse
Protein G purified
Chemokines and Cytokines, Cytokine Research, GPCR, Immunology, Innate Immunity, Signal Transduction
3577.0
Store at 4°C in the dark. Do not freeze.
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.